SAR 156597

Drug Profile

SAR 156597

Alternative Names: Bispecific IL4/IL13 antibody - sanofi-aventis; IL4/IL13 bi-specific monoclonal antibody - sanofi-aventis; SAR156597; SUB33159

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Systemic scleroderma

Most Recent Events

  • 14 Aug 2017 Sanofi completes a phase II trial in Idiopathic pulmonary fibrosis (In the elderly, In adults) in USA, Canada, Czech Republic and Denmark, Argentina, Chile, Colombia, France, Germany, Greece, Israel, Italy, Mexico, Spain, Turkey, Australia, South Korea, Portugal and United Kingdom (NCT02345070)
  • 05 Oct 2016 Preclinical trials in Systemic scleroderma in USA (SC) (NCT02921971)
  • 01 Oct 2016 Phase-II clinical trials in Systemic scleroderma in United Kingdom (SC) (NCT02921971)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top